Hutchens & Kramer Investment Management Group LLC Sells 3,715 Shares of Eli Lilly and Company $LLY

Hutchens & Kramer Investment Management Group LLC reduced its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 44.0% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 4,722 shares of the company’s stock after selling 3,715 shares during the quarter. Eli Lilly and Company makes up about 1.8% of Hutchens & Kramer Investment Management Group LLC’s portfolio, making the stock its 11th biggest holding. Hutchens & Kramer Investment Management Group LLC’s holdings in Eli Lilly and Company were worth $5,075,000 at the end of the most recent quarter.

Other institutional investors have also made changes to their positions in the company. Brighton Jones LLC boosted its position in Eli Lilly and Company by 22.0% during the fourth quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock worth $7,409,000 after purchasing an additional 1,730 shares during the period. Revolve Wealth Partners LLC increased its holdings in shares of Eli Lilly and Company by 2.8% in the fourth quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock valued at $1,136,000 after purchasing an additional 40 shares during the last quarter. Schnieders Capital Management LLC. raised its position in shares of Eli Lilly and Company by 16.7% in the second quarter. Schnieders Capital Management LLC. now owns 7,993 shares of the company’s stock valued at $6,231,000 after purchasing an additional 1,141 shares during the period. Proactive Wealth Strategies LLC raised its position in shares of Eli Lilly and Company by 5.6% in the second quarter. Proactive Wealth Strategies LLC now owns 1,398 shares of the company’s stock valued at $1,090,000 after purchasing an additional 74 shares during the period. Finally, Titleist Asset Management LLC lifted its stake in shares of Eli Lilly and Company by 48.6% during the 2nd quarter. Titleist Asset Management LLC now owns 789 shares of the company’s stock worth $615,000 after buying an additional 258 shares during the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several analysts recently commented on the stock. CICC Research lifted their target price on shares of Eli Lilly and Company from $1,060.00 to $1,107.00 and gave the stock a “neutral” rating in a report on Wednesday, February 11th. Scotiabank reissued an “outperform” rating and issued a $1,300.00 price target on shares of Eli Lilly and Company in a report on Thursday, February 5th. TD Cowen raised their price objective on shares of Eli Lilly and Company from $960.00 to $1,250.00 and gave the stock a “buy” rating in a research report on Thursday, January 29th. Guggenheim boosted their price objective on Eli Lilly and Company from $1,161.00 to $1,168.00 and gave the stock a “buy” rating in a report on Thursday, February 26th. Finally, Truist Financial reaffirmed a “buy” rating on shares of Eli Lilly and Company in a research report on Monday, February 23rd. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $1,221.44.

Eli Lilly and Company Price Performance

NYSE:LLY opened at $910.59 on Tuesday. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $1,133.95. The firm has a market cap of $860.34 billion, a price-to-earnings ratio of 39.68, a P/E/G ratio of 1.05 and a beta of 0.40. The firm’s 50-day simple moving average is $1,019.76 and its 200 day simple moving average is $960.48. The company has a debt-to-equity ratio of 1.54, a quick ratio of 1.19 and a current ratio of 1.58.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Wednesday, February 4th. The company reported $7.54 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $7.48 by $0.06. Eli Lilly and Company had a net margin of 31.66% and a return on equity of 102.94%. The firm had revenue of $19.29 billion during the quarter, compared to the consensus estimate of $17.85 billion. During the same quarter in the previous year, the firm posted $5.32 EPS. The business’s revenue for the quarter was up 42.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. As a group, sell-side analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current year.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Expanded patient access/pricing for Zepbound — Lilly will offer a self-pay option starting at $299/month for a low dose and expand distribution via LillyDirect and major pharmacies, which could widen the addressable market and reduce payer friction. Eli Lilly Expands Zepbound Access
• Positive Sentiment: Analysts trimming and raising targets after strong quarterly results — multiple outlets note analyst upgrades and upside estimates following Lilly’s February quarter beats and raised FY‑2026 EPS guidance, supporting investor confidence. Analyst Upside Coverage
• Positive Sentiment: Positive Phase‑3 ADorable‑1 topline results announced — a favorable readout (topline) from a Phase‑3 trial bolsters pipeline optionality beyond weight‑loss products, which could add long‑term value if confirmed in full data and regulatory filings. ADorable-1 Topline Results
• Positive Sentiment: Manufacturing / international expansion discussions — Lilly leadership is engaged with Indian officials on “Make in India” steps, signaling potential capacity/market expansion outside the U.S. that could support production and revenue growth. Make in India Meeting
• Neutral Sentiment: Executives ramping China engagement — Lilly joined U.S. peers at the China Development Forum; management signals cautious investment in China, which is an opportunity for growth but carries geopolitical and execution risks. China Development Forum Coverage
• Neutral Sentiment: Local permitting / community concerns around new plant — planners in Lehigh Valley will discuss traffic and other issues tied to a proposed Lilly site; routine for expansion but could delay timelines. Lehigh Valley Plant Discussion
• Negative Sentiment: Supreme Court revives Actos litigation — the court’s action reopens potential legal exposure tied to Actos, creating an earnings/contingent‑liability risk that investors will watch for scope and financial impact. Actos Litigation Revival

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.